CIPLA: CO GETS FINAL APPROVAL FROM US FDA FOR NEW DRUG APPLICATION (NDA) SUBMITTED FOR NILOTINIB CAPSULES 50, 150 & 200 MG || NILOTINIB IS USED FOR TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML) || PRODUCT IS EXPECTED TO BE LAUNCHED IN FY2025-26 IN USA